Literature DB >> 33213734

Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients: The ISAR-REACT 5 Trial.

Katharina Mayer, Dario Bongiovanni, Vincent Karschin, Dirk Sibbing, Dominick J Angiolillo, Heribert Schunkert, Karl-Ludwig Laugwitz, Stefanie Schüpke, Adnan Kastrati, Isabell Bernlochner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33213734     DOI： 10.1016/j.jacc.2020.09.586

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  6 in total

1.  Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Analysis from the Acute Coronary Syndrome Israeli Survey.

Authors:  Ran Eliaz; Bethlehem Mengesha; Tal Ovdat; Zaza Iakobishvili; David Hasdai; Mark Kheifets; Robert Klempfner; Roy Beigel; Eran Kalmanovich; Ronny Alcalai; Amos Levi
Journal:  Cardiology       Date:  2021-11-22       Impact factor: 2.342

2.  Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes.

Authors:  Gjin Ndrepepa; Stefan Holdenrieder; Isabell Bernlochner; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2021-12-01       Impact factor: 6.138

3.  Comparative efficacy and safety of oral P2Y12 inhibitors after non-ST-elevation acute coronary syndromes: a network meta-analysis.

Authors:  Ioannis T Farmakis; Stefanos Zafeiropoulos; Ioannis Doundoulakis; Areti Pagiantza; Efstratios Karagiannidis; Dimitrios V Moysidis; Nikolaos Stalikas; George Kassimis; Lampros K Michalis; Haralambos Karvounis; George Giannakoulas
Journal:  Open Heart       Date:  2022-04

Review 4.  Antiplatelet Therapy for Atherothrombotic Disease in 2022-From Population to Patient-Centered Approaches.

Authors:  Georges Jourdi; Anne Godier; Marie Lordkipanidzé; Guillaume Marquis-Gravel; Pascale Gaussem
Journal:  Front Cardiovasc Med       Date:  2022-01-28

5.  Protease-activated receptor-mediated platelet aggregation in patients with type 2 diabetes on potent P2Y12 inhibitors.

Authors:  Benjamin Panzer; Patricia P Wadowski; Kurt Huber; Simon Panzer; Thomas Gremmel
Journal:  Diabet Med       Date:  2022-05-16       Impact factor: 4.213

6.  NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View.

Authors:  Denis Angoulvant; Pierre Sabouret; Michael P Savage
Journal:  Am J Cardiovasc Drugs       Date:  2021-03-06       Impact factor: 3.571
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.